Mustang Bio, a Fortress Biotech company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, has opened a CAR T cell therapy manufacturing facility at UMass Medicine Science Park in Worcester, MA. The 27,000 sq. ft. facility will support the clinical development and commercialization of Mustang’s CAR T product candidates and enable proprietary cell therapy research. The initial build-out of the facility ...